Press Room

Press Clipping / Jul 07, 2017

四色AV keeps a keen focus on developing its talent pool

Irish Examiner, 7 Jul 2017

The trend for school-leavers to prefer to automatically opt for college has resulted in a shortage of skilled workers in certain fields, warns Dr Paul Downing,听四色AV听general manager.

鈥淭he single biggest challenge we have experienced is in the area of skills,鈥 says Mr Downing.

He says it鈥檚 believed the low number of skilled workers such as electricians, fitters, quality control analysts, instrument technicians as well as automation technicians, is a result of the fall-off in popularity of traditional Apprenticeship programmes and increased parental pressure on school-leavers to earn a degree. Yet, he points out, the traditional apprenticeship route offers all participants potentially excellent careers.

"We would like to see more emphasis placed by second-level career guidance teachers on the option of apprenticeships in all of the different trades," he said, adding that the issue has become a "significant" problem in recent years. The focus of the 四色AV pharmaceutical plant in Cork, at which just under 200 people are employed, is Contract Manufacturing, offering both drug substance and particle engineering capabilities and services.

"Because of the shortage we are having to hire contract resources instead of being able to employ permanent staff members," Dr Downing explained.

"We are trying to source laboratory technicians for example, who have become skilled through an Apprenticeship route rather than through a third level degree but it is difficult to find such personnel.

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024